# Factors Released by Polarized Neutrophil-like Cells Modulate Cardiac Fibroblast Phenotype and Limit the Inflammatory Response After Myocardial Infarction

**Authors:** Letitia Ciortan, Ana-Maria Gan, Sergiu Cecoltan, Mihaela Serbanescu, Andreea Cristina Mihaila, Razvan Daniel Macarie, Monica Madalina Tucureanu, Miruna Larisa Naie, Mihai Bogdan Preda, Bogdan-Paul Cosman, Galyna Bila, Rostyslav Bilyy, Elena Butoi

PMC · DOI: 10.3390/biomedicines13112829 · 2025-11-20

## TL;DR

This study shows that factors from different types of neutrophils can influence heart fibroblasts and reduce inflammation after a heart attack.

## Contribution

The novel finding is that both pro- and anti-inflammatory neutrophil-derived factors limit inflammation and fibrosis in cardiac healing after MI.

## Key findings

- N1 neutrophil factors induce a pro-inflammatory and matrix-degrading fibroblast phenotype in vitro.
- Both SN1 and SN2 treatments reduce inflammation and fibrotic markers in the infarcted heart in vivo.
- N1/N2-derived mediators promote a balanced reparative response during cardiac healing.

## Abstract

Background: Following myocardial infarction (MI), cardiac fibroblasts (CFs) adopt distinct phenotypes to ensure scar formation and healing. Although leukocytes are a critical driver of post-MI healing, the role of neutrophils in modulating CF phenotype remains insufficiently explored. We therefore investigated the impact of soluble mediators released by neutrophil subtypes found post-MI—pro-inflammatory (N1) and anti-inflammatory (N2)—on shaping CFs phenotype. Methods: In vitro, human 3D grown CFs were indirectly co-cultured with N1 or N2 neutrophil-like cells using a two-chamber Transwell system. After 24 h, expression of inflammatory, remodeling, and pro-fibrotic markers was evaluated in fibroblasts and conditioned media. In vivo, soluble mediators derived from polarized mouse neutrophils (SN1 or SN2) were injected into the infarcted myocardium of C57BL/6J after MI surgery. The effects on the healing process were investigated at 1 and 7 days post-MI. Results: In vitro, CFs were found to exhibit a pro-inflammatory and matrix-degrading phenotype following indirect co-culture with N1 cells, characterized by overexpression of IL-1β, IL-6, MCP-1, and metalloproteases MMP-3/MMP-9. In vivo, both SN1 and SN2 treatments significantly reduced pro-inflammatory markers IL-1β and IL-6 gene expression at day 1 post-MI (inflammatory phase). At day 7 post-MI (resolution phase), SN1/SN2 treatments continued to limit local inflammation, while mitigating fibrotic remodeling by reducing CCN2, α-SMA, and key extracellular matrix proteins. Conclusions: Together, these findings suggest that while N1-derived mediators promote a pro-inflammatory fibroblast phenotype in vitro, factors secreted by both N1 and N2 support a more balanced reparative response in vivo, by limiting local inflammation and potentially mitigating adverse remodeling post-MI.

## Linked entities

- **Genes:** IL1B (interleukin 1 beta) [NCBI Gene 3553], IL6 (interleukin 6) [NCBI Gene 3569], CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347], MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314], MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318], CCN2 (cellular communication network factor 2) [NCBI Gene 1490], ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58]
- **Diseases:** myocardial infarction (MONDO:0005068)

## Full-text entities

- **Genes:** CCN2 (cellular communication network factor 2) [NCBI Gene 1490] {aka CTGF, HCS24, IBP-8, IGFBP8, KMD, NOV2}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, SLC38A3 (solute carrier family 38 member 3) [NCBI Gene 10991] {aka DEE102, G17, NAT1, SN1, SNAT3}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, SLC38A5 (solute carrier family 38 member 5) [NCBI Gene 92745] {aka JM24, SN2, SNAT5, pp7194}
- **Diseases:** CF (MESH:D003550), MI (MESH:D009203), infarcted myocardium (MESH:D007238), Inflammatory (MESH:D007249)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), N1 — Mus musculus (Mouse), Transformed cell line (CVCL_D425)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12650109/full.md

---
Source: https://tomesphere.com/paper/PMC12650109